Status:

COMPLETED

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Lead Sponsor:

Supernus Pharmaceuticals, Inc.

Conditions:

Attention Deficit Disorder With Hyperactivity

Conduct Disorder

Eligibility:

All Genders

6-12 years

Phase:

PHASE2

Brief Summary

The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.

Detailed Description

This will be a randomized, multicenter, parallel group, dose-ranging safety and tolerability study in children with ADHD and persistent serious conduct problems. The target subjects are healthy male o...

Eligibility Criteria

Inclusion

  • Healthy pediatric male or female subjects, age 6 to 12 years.
  • Diagnostic and Statistical Manual of Mental Disorders - IV -Text Revision (DSM-IV-TR) diagnosis of ADHD.
  • NCBRF-TIQ disruptive behavior disorder subscale 27 or greater at baseline; AND a score of 2 or more on at least 1 of the following 3 items of the conduct problem subscale: knowingly destroys property, gets in physical fights, physically attacks people.
  • IQ greater than 71.

Exclusion

  • Current or lifetime diagnosis of bipolar disorder, post-traumatic stress disorder, personality disorder, or psychosis not otherwise specified.
  • Currently meeting DSM-IV-TR criteria for major depressive disorder, obsessive compulsive disorder, or pervasive developmental disorder.
  • Any other anxiety disorder as primary diagnosis.
  • Use of anticonvulsants, antidepressants, lithium, carbamazepine, valproic acid, or cholinesterase inhibitors within 2 weeks of baseline.
  • Unstable endocrinological or neurological conditions which confound the diagnosis or are a contraindication to treatment with antipsychotics.

Key Trial Info

Start Date :

October 21 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 23 2009

Estimated Enrollment :

78 Patients enrolled

Trial Details

Trial ID

NCT00626236

Start Date

October 21 2008

End Date

September 23 2009

Last Update

December 9 2025

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Florida Clinical Research Center

Bradenton, Florida, United States, 32408

2

Sarkis Clinical Trials

Gainesville, Florida, United States, 32607

3

CNS Healthcare

Orlando, Florida, United States, 32806

4

Capstone Clinical Research

Libertyville, Illinois, United States, 60048

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems | DecenTrialz